【摘要】 目的 回顾性分析类风湿关节炎患者使用托法替布治疗后发生感染的相关影响因素。方法 收集2022年1月至2023年12月重庆市中医院风湿免疫科使用托法替布治疗的211例类风湿关节炎患者的病例资料，根据是否发生感染对其进行分组，对性别、年龄、中医证型、服用中药时间、合并肺系疾病情况及治疗前后淋巴细胞计数等因素进行单因素检验后，将差异有统计学意义的因素纳入logistic回归分析。结果 脾虚夹湿证、服用中药时间1～4周及>4～<8周为类风湿关节炎患者使用托法替布后感染发生的保护因素(OR=0.427,95%CI:0.184～0.988,P<0.05;OR=0.233,95%CI:0.093～0.580,P<0.05;OR=0.328,95%CI:0.135～0.799,P<0.05);而合并有肺间质病变及支气管扩张为使用托法替布后感染发生的危险因素(OR=3.000,95%CI:1.306～6.894,P<0.05;OR=16.615,95%CI:1.782～154.945,P<0.05)。结论 类风湿关节炎患者使用托法替布后感染的发生风险与中医证型、服用中药时间及肺系疾病密切相关。更多还原

【Abstract】 Objective To retrospectively analyze the related influencing factors of the infection occurrence after using tofacitinib in the patients with rheumatoid arthritis.Methods The case data of 211 patients with rheumatoid arthritis treated by tofacitinib in the rheumatology and immunology department of Chongqing Municipal Hospital of Traditional Chinese Medicine from January 2022 to December 2023 were collected.The patients were grouped according to whether infection occurred or not.After single factor test on gender, age, Chinese medicine syndromes, time of taking Chinese medicine, lung system diseases and lymphocyte count, then the factors with statistically significant differences were included in the Logistic regression analysis.Results Spleen deficiency and dampness syndrome, taking traditional Chinese medicine time 1-4 weeks, and >4-<8 weeks were the protective factors for the infection occurrence after using tofacitinib in rheumatoid arthritis(OR=0.427,95%CI:0.184-0.988,P<0.05;OR=0.233,95%CI:0.093-0.580,P<0.05;OR=0.328,95%CI:0.135-0.799,P<0.05),complicating pulmonary interstitial lesions and bronchiectasis were the risk factors for infection occurrence after using tofactitinib(OR=3.000,95%CI:1.306-6.894,P<0.05;OR=16.615,95%CI:1.782-154.945,P<0.05).Conclusion The risk of infection occurrence after using tofacitinib in the patients with rheumatoid arthritis is closely correlated with Chinese medicine syndromes, time of taking Chinese medicine and lung system diseases.更多还原